Fundamental Analysis of IGM BIOSCIENCES INC(NASDAQ:IGMS) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to IGMS. IGMS was compared to 564 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IGMS as it has an excellent financial health rating, but there are worries on the profitability. IGMS is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

IGMS had negative earnings in the past year.

In the past year IGMS has reported a negative cash flow from operations.

IGMS had negative earnings in each of the past 5 years.

In the past 5 years IGMS always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -65.50%, IGMS is doing worse than 64.35% of the companies in the same industry.

The Return On Equity of IGMS (-180.13%) is worse than 67.20% of its industry peers.

		Industry Rank	Sector Rank
ROA	-65.5%
ROE	-180.13%
ROIC	N/A

ROA(3y)-52.22%

ROA(5y)-38.61%

ROE(3y)-88.55%

ROE(5y)-60.98%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IGMS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IGMS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, IGMS has more shares outstanding

IGMS has more shares outstanding than it did 5 years ago.

There is no outstanding debt for IGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

IGMS has an Altman-Z score of -2.63. This is a bad value and indicates that IGMS is not financially healthy and even has some risk of bankruptcy.

IGMS has a Altman-Z score (-2.63) which is in line with its industry peers.

IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.63

ROIC/WACCN/A

WACC10.8%

2.3 Liquidity

A Current Ratio of 7.06 indicates that IGMS has no problem at all paying its short term obligations.

IGMS's Current ratio of 7.06 is fine compared to the rest of the industry. IGMS outperforms 67.38% of its industry peers.

IGMS has a Quick Ratio of 7.06. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 7.06, IGMS is doing good in the industry, outperforming 67.38% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.06
Quick Ratio	7.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IGMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.36%, which is quite impressive.

IGMS shows a strong growth in Revenue. In the last year, the Revenue has grown by 74.37%.

EPS 1Y (TTM)30.36%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%44.76%

Revenue 1Y (TTM)74.37%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%179.91%

3.2 Future

Based on estimates for the next years, IGMS will show a small growth in Earnings Per Share. The EPS will grow by 7.50% on average per year.

Based on estimates for the next years, IGMS will show a very strong growth in Revenue. The Revenue will grow by 172.74% on average per year.

EPS Next Y34.33%

EPS Next 2Y21.47%

EPS Next 3Y15.02%

EPS Next 5Y7.5%

Revenue Next Year256.53%

Revenue Next 2Y66.23%

Revenue Next 3Y112.86%

Revenue Next 5Y172.74%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGMS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

IGMS's earnings are expected to grow with 15.02% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y21.47%

EPS Next 3Y15.02%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IGMS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IGM BIOSCIENCES INC

NASDAQ:IGMS (11/4/2024, 8:15:55 PM)

After market: 15.69 0 (0%)

15.69

-0.53 (-3.27%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap930.73M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-65.5%
ROE	-180.13%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.06
Quick Ratio	7.06
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)30.36%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y34.33%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)74.37%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

IGM BIOSCIENCES INC (IGMS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens